DDISCOVRWES image.png

Brief Summary

The DDISCOVRWES project outlines an innovative strategy for continuous real-world data assessment to support drug development and label expansion, with a particular focus on advancing precision medicine approaches. It underlines that real world evidence can lead to new discovery regarding the medical product, not tractable for study via clinical trials. It proposes a novel framework that goes beyond traditional applications of real-world evidence, aiming to unlock new potentials in biomarker-based treatments and personalized healthcare. By introducing a matrix-based approach that considers both disease and treatment perspectives, along with biomarker presence, the project seeks to provide a comprehensive and dynamic understanding of drug efficacy and market potential throughout a product's lifecycle.

Expanded Summary

Background and Objectives

Real-world evidence (RWE) has emerged as a powerful tool in healthcare research and decision-making, complementing traditional randomized controlled trials (RCTs). The DDISCOVRWES project aims to provide a comprehensive strategy for leveraging real-world data to support drug development and label expansion. This approach recognizes the evolving landscape of healthcare data and seeks to maximize its potential for improving patient outcomes and driving pharmaceutical innovation.

The project's main objectives include:

  1. Developing a framework for continuous assessment of real-world data in drug development.
  2. Identifying key areas where RWE can provide valuable insights beyond traditional clinical trials.
  3. Proposing novel approaches to analyze real-world data for precision medicine and label expansion.

Current Landscape of RWE Utilization

The project identifies four main areas of RWE application:

  1. Clinical trial complementation/support
  2. Understanding subgroups for label expansion and precision medicine
  3. Understanding population metrics of diseases with and without treatments
  4. Understanding cost-effectiveness

Current evidence suggests that RWE is primarily focused on supporting clinical trials, understanding real-world disease patterns and treatment outcomes, and informing cost-effectiveness analyses. The use of RWE for precision medicine and label expansion, while promising, appears to be less developed and adopted.

Proposed Framework for Continuous Real-World Data Assessment

The DDISCOVRWES project introduces a novel framework for analyzing real-world data, categorized into four main areas: